Edition:
United States

Vital Therapies Inc (VTL.OQ)

VTL.OQ on NASDAQ Stock Exchange Global Select Market

0.43USD
4:00pm EDT
Change (% chg)

$0.18 (+70.09%)
Prev Close
$0.25
Open
$0.26
Day's High
$0.47
Day's Low
$0.26
Volume
6,748,972
Avg. Vol
224,216
52-wk High
$9.70
52-wk Low
$0.25

Chart for

About

Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy... (more)

Overall

Beta: 4.50
Market Cap(Mil.): $10.68
Shares Outstanding(Mil.): 42.37
Dividend: --
Yield (%): --

Financials

  VTL.OQ Industry Sector
P/E (TTM): -- 103.50 32.14
EPS (TTM): -1.28 -- --
ROI: -108.40 1.52 12.66
ROE: -108.51 0.25 14.84

Vital Therapies shares dive as liver system fails trial

U.S. biotech firm Vital Therapies Inc said it will explore strategic options after its liver disease treatment failed to meet the main goal of a late-stage study, driving its shares down more than 70 percent on Wednesday.

Sep 12 2018

Vital Therapies shares dive as liver system fails trial

Sept 12 U.S. biotech firm Vital Therapies Inc said it will explore strategic options after its liver disease treatment failed to meet the main goal of a late-stage study, driving its shares down more than 70 percent on Wednesday.

Sep 12 2018

BRIEF-Vital Therapies Q1 Loss Per Share $0.34

* VITAL THERAPIES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

BRIEF-Vital Therapies Announces VTL-308 Reaches Enrollment Target Of 150 Subjects

* VITAL THERAPIES ANNOUNCES VTL-308 REACHES ENROLLMENT TARGET OF 150 SUBJECTS

Mar 22 2018

Earnings vs. Estimates